Given their pro-tumorigenic function and prevalence in most malignant tumors with lower 28 survival, early detection and intervention of CD206-positive M2-macrophages may boost the 29 clinical outcome. To determine in vivo distribution of M2-macrophages, we adopted 111 In-oxine-30 based radiolabeling of the targeted exosomes. When injected these radiolabeled targeted exosomes 31 into breast tumor-bearing mice, exosomes accumulated at the periphery of the primary tumor, 32 metastatic foci in the lungs, spleen, and liver. Ex vivo quantification of radioactivity also showed 33 similar distribution. Injected DiI dye-labeled exosomes into the same mice showed adherence of 34 exosomes to the CD206-positive M2-macrophages on ex vivo fluorescent microscopy imaging. In 35 addition, we utilized these engineered exosomes to carry the Fc portion of IgG2b with the intention 36 of augmenting antibody-dependent cell-mediated cytotoxicity. We have auspiciously 37 demonstrated that M2-macrophage targeting therapeutic exosomes deplete M2-macrophages both 38 in vitro and in vivo, and reduce tumor burden increasing survival in a metastatic breast cancer 39 model.
enable the design of rational therapies that specifically target TAMs, ideally leaving normal lipids and depletes more than 90% macrophages in spleen after a single intravenous injection 24, 140 25 . Clophosome®-A is not approved for human studies, and it is for experimental use only. 141 Similar to the previously-mentioned 131 I-labeled exosomes 26 , prior to IV injection into mice for 142 biodistribution, we checked the labeling efficiency of 111 In-oxine to the engineered exosomes 143 and serum stability of binding by thin layer paper chromatography (TLPC). While approximately 144 92% of the free 111 In-oxine alone moved from the spotted point in the bottom to the top half of 145 the TLPC paper (Figure 3a) , more than 98% of 111 In-oxine-bound to the engineered exosomes 146 remained at the bottom, indicating that 111 In-oxine was bound to the engineered exosomes with 147 very little dissociation of the 111 In-oxine from the exosomes (Figure 3b ). After labeling with 148 111 In-oxine we also evaluated serum stability of the binding through incubating the labeled 149 exosomes with 20% FBS for 1 hour and 24 hours. TLPC showed that > 92% of 111 In-oxine was 150 still bound to exosomes after 1 and 24 hours (Figure 3c ). injected with 111 In-oxine-labeled M2-targeting exo compared to other two groups (Figure 3f) . 169 Following the scan, animals were euthanized, and radioactivity of different organs were 170 determined as reported previously 27, 28 . Alike in vivo, ex vivo quantification of radioactivity also 171 showed substantially higher radioactivity in lungs, spleen and tumor of animals injected with 111 In-172 oxine-labeled M2-targeting exo (Figure 3g) . 173 Following the confirmation of targeting potential of engineered exosomes for diagnostic purpose, 176 we utilize the exosomes as therapeutic carriers. We conjugated Fc portion of mouse IgG2b next 177 to the targeting precision peptide with a small linker with the purpose of inducing ADCC 178 (Figure 4a and 4b) . Identical to the previous construct, 6XHis tag and luciferase were 179 incorporated as reporter genes.
180
Positively selected cells showed strong luciferase activity in vitro following addition of luciferin 181 substrate while non-transfected HEK293 cells did not show any activity (Figure 4c) . We 182 confirmed the presence of Fc portion of mouse IgG2b on the surface of the exosomes by flow-183 cytometry using FITC-conjugated anti-mouse IgG2b antibody, that showed ~52% of engineered 184 therapeutic exosomes express Fc portion of mouse IgG2b (Figure 4d) . 185 We next analyzed concentration and size distribution of the engineered therapeutic exosomes by 186 NTA (Figure 4e) . The mean diameter of engineered exosomes was significantly larger than the 187 non-engineered exosomes (Figure 4f) . TEM images for engineered therapeutic exosomes 188 showed distinctive round morphology and size without any distortion (Figure 4g) . Flow-189 cytometric analysis of common exosome markers for the engineered exosomes showed ~48% 190 positive for CD9 and ~40% positive for CD63 (Figure 4h ). To ascertain the capacity of therapeutic exosomes for instigating ADCC, we treated the CFSE- whereas no metastasis was detected in treated animals after 6 weeks. (d) Quantification of optical density 544 of the tumor area also showed decreased tumor growth in treated group compared to control group. 545
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Quantitative data are expressed in mean ± SEM. n = 3. (e) Kaplan-Meier plot showing prolonged survival 546 of the mice treated with therapeutic engineered exosomes. 547
